Lending a helping hand for your AAV and RNA-LNP workflow needs
Genomic medicines such as viral vector-based gene therapies and RNA lipid nanoparticles (RNA-LNPs) are breaking new ground. While there has been much progress bringing new therapeutics to life, there’s almost unlimited potential for these technologies to bloom and grow.
As you innovate your science, we’re innovating to help you develop, discover, and deliver them to the clinic and beyond ― faster and more cost effectively than ever before. Whatever route you’re choosing for gene delivery, we’ve got you covered.
RNA-LNPs
In case you haven’t heard, Precision NanoSystems is now part of Cytiva. The innovation continues with an ever-expanding toolbox of equipment, kits, reagents, services, and know-how to formulate your RNA-LNPs.
If you’re headed to ASGCT 2024, take in our talk about engineering T cell and HSCs, stop by our posters, or visit us at booth #1717 to chat and see how our NanoAssmblr™ instruments work. And hear about an exciting kit we just launched.
Can’t attend the conference? No worries ― Email Ammad Bilal to discuss your needs.
Cell lines for AAV manufacturing
The lack of choice in cell lines has been a pain point for making viral vectors. Until now. We’re introducing ELEVECTA™ cell lines ― a leap forward in AAV manufacturing. Head over to booth #1717 to talk to our specialists. And don’t miss out on our talks and posters.
Whether or not we see you at the conference, sign up to get access to exclusive resources that will help you understand your cell line options.
Regulatory insights
How to get potential therapies through the regulatory process is a common concern. If this resonates, check out the sessions with two of our lead regulatory strategists to help you unravel the complexities.
Navigate the tabs below to check out more details on our talks and what to expect at the booth!
Insert text
Acrodisc® Syringe Filters
Reliable Results with Superior Protection
Insert text
Form title
Form sub title
Insert text
Panel 2 header
Insert text
Panel 3 header
Insert text
Follow our connected mAb perfusion process
Insert text
Insert text
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
Curious about continuous biomanufacturing? Join the Cytiva project team vlog series as we document our proof of concept trial and provide insights to help you efficiently plan and execute your project .
What are the talks about?
Thursday, May 9 | 12:15–1:15 PM | Room 327-329
Presented by:
Clive Glover (Cytiva) and Sybil Danby (Cytiva)
Panel discussion:
Barry Byrne (Powell Gene Therapy Center at the University of Florida)
Kimberly Benton (Dark Horse Consulting)
Markus Haindl (Roche Diagnostics)
Nicole Paulk (Siren Biotechnology)
Ex vivo engineering of T cells and hematopoietic stem cells using RNA-lipid nanoparticles for cell and gene therapies
Thursday, May 9 | 4:45-5:15 PM | Room 337-338
Dr. Angela Zhang, Product Management Leader (Cytiva)
Generation of a stable high-titer production cell line for therapeutic AAV vectors
Friday, May 10 | 5:15-5:30 PM | Ballroom 3 (Abstract #295)
Stefan Seeber (Roche)
Systematic analysis of primary field data from biologics therapy regulatory non-approvals: Why aren’t we talking about FDA rejections?
Wednesday, May 8 | 5:10-5:27pm | Rooms 314-317
Limin Wang, Lead Regulatory Strategist (Cytiva)
What’s at the booth?
Get hands-on with some of our newest offerings:
For viral vectors
ELEVECTA™ cell line portfolio
Make AAV your way ― choose from transient, packaging, and producer options.
iCELLis™ Nano bioreactor
Making viral vectors in adherent cells? Get industrial performance from our benchtop fixed-bed bioreactor, with the option to scale up to a larger model.
Xcellerex™ X-platform bioreactor
Or are you making them in suspension? Ask about automation options, digital tools, and remote monitoring in our newest single-use, stirred-tank bioreactor platform.
For RNA-LNPs
NanoAssemblr™ systems
Working with expensive materials? We recommend the NanoAssemblr™ Spark™ system for target validation screening and nanoparticle formulation development.
Or perhaps you’re assembling LNPs for preclinical studies? In that case, the NanoAssemblr™ Ignite™ system enables controlled and precise assembly using NxGen™ microfluidic technology.